A Phase 2 interventional study of Mitoxantrone hydrochloride and Etoposide in Lymphoma, Non-Hodgkin and HIV Infections, sponsored by Lederle Laboratories. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Lederle Laboratories · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing etoposide in Lymphoma, Non-Hodgkin — 3 open to participants now, 6 under way, 1 of them phase 3. Etoposide · Lymphoma, Non-Hodgkin.
Among the 64 studies testing etoposide in Lymphoma, Non-Hodgkin, this one is one of 41 in phase 2, and was the 12th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 64 studies testing etoposide in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
The Affiliated People's Hospital of Ningbo University · Sites in China
Ages 18–75
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
New York Medical College · Sites in United States
Ages 3–31
By country, each count listing its studies:
Etoposide: first FDA approval 1983 (VEPESID). What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 49 · Phase 3 6
First in 1988; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 42 across the 59 interventional studies. Of the 49 that completed or were terminated, 24 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 64 have an industry lead sponsor. The 10 most frequent:
Lederle Laboratories is the lead sponsor of 6 studies on the registry; none are open to participants now.
Lederle Laboratories has 1 study filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
3 of the studies testing etoposide in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT01840566Memorial Sloan Kettering Cancer CenterHigh Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | 2027-04 |
| NCT03125642Masonic Cancer Center, University of MinnesotaAuto Stem Cell Transplant for Lymphoma Patients | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 64 studies testing etoposide in Lymphoma, Non-Hodgkin, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have the following:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 2 weeks of study entry:
Prior Treatment:
Excluded:
Required:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Mar 1992. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mitoxantrone · Etoposide
Lederle Laboratories